A network-based classification model for deriving novel drug-disease associations and assessing their molecular actions

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Oh, Min ^a   Ahn, Jaegyoon ^b   Yoon, Youngmi ^a  

^a Gachon University College of Medicine   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL; TELMISARTAN; DRUG;

ARTICLE; CALCULATION; DRUG DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MEDICAL PARAMETERS; PREDICTION; PROTEIN PROTEIN INTERACTION; RANDOM FOREST; SCORING SYSTEM; AREA UNDER THE CURVE; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DATA BASE; DISEASES; GENE REGULATORY NETWORK; GENETICS; METABOLISM; REPRODUCIBILITY; TOXICOGENETICS;

AREA UNDER CURVE; CLINICAL TRIALS AS TOPIC; DATABASES AS TOPIC; DISEASE; GENE REGULATORY NETWORKS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; TOXICOGENETICS;

EID: 84909606201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111668     Document Type: Article

References (44)

1. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nature chemical biology 4(11):682-690.
2. Cheng F, Liu C, Jiang J, Lu W, Li W, et al. (2012) Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS computational biology 8(5):e1002503.
3. Chong CR, Sullivan DJ (2007) New uses for old drugs. Nature 448:645-646.
4. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321(5886):263-266.
5. Schadt EE, Friend SH, Shaywitz DA (2009) A network view of disease and compound screening. Nature reviews Drug discovery 8(4):286-295.
6. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462(7270):175-181.
7. Dudley JT, Deshpande T, Butte AJ (2011) Exploiting drug-disease relationships for computational drug repositioning. Briefings in bioinformatics 12(4):303-311.
8. Hu G, Agarwal P (2009) Human disease-drug network based on genomic expression profiles. PLoS One 4(8):e6536.
9. Suthram S, Dudley JT, Chiang AP, Chen R, Hastie TJ, et al. (2010) Networkbased elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS computational biology 6(2):e1000662.
10. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science translational medicine 3(96):96ra77-96ra77.
11. Zhao S, Li S (2012) A co-module approach for elucidating drug-disease associations and revealing their molecular basis. Bioinformatics 28(7):955-961.
12. Gottlieb A, Stein GY, Ruppin E, Sharan R (2011) PREDICT: a method for inferring novel drug indications with application to personalized medicine. Molecular systems biology 7(1):496.
13. Brown KR, Jurisica I (2007) Unequal evolutionary conservation of human protein interactions in interologous networks. Genome biology 8(5):R95.
14. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, et al. (2009) PID: the pathway interaction database. Nucleic acids research (suppl 1): D674-D679.
15. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic acids research (suppl 1): D1035-D1041.
16. McKusick VA (2007) Mendelian Inheritance in Man and its online version, OMIM. American journal of human genetics 80(4):588.
17. Davis AP, Murphy CG, Saraceni-Richards CA, Rosenstein MC, Wiegers TC, et al. (2009) Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic acids research (suppl 1): D786-D792.
18. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, et al. (2009) The WEKA data mining software: an update. ACM SIGKDD explorations newsletter 11(1):10-18.
19. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. science 313(5795):1929-1935.
20. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human disease network. Proceedings of the National Academy of Sciences 104(21):8685-8690.
21. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, et al. (2013) Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Annals of oncology 24(5):1312-1319.
22. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. Journal of clinical oncology 29(19):2635-2644.
23. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, et al. (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. Journal of clinical oncology 29(19):2645-2652.
24. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, et al. (2010) Betablocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628.
25. Al-Wadei HA, Ullah MF, Al-Wadei MH (2012) Intercepting neoplastic progression in lung malignancies via the beta adrenergic (β-AR) pathway: Implications for anti-cancer drug targets. Pharmacological Research 66(1):33-40.
26. Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ (1991) Model systems for the study of seven-transmembrane-segment receptors. Annual review of biochemistry 60(1):653-688.
27. Schuller HM (2009) Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nature Reviews Cancer 9(3):195-205.
28. Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clinical cancer research 18(5):1201-1206.
29. Vigil D, Cherfils J, Rossman KL, der CJ (2010) Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy. Nature Reviews Cancer 10(12):842-857.
30. Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, et al. (2012) Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery 11(11):833-846.
31. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, et al. (2009) Cognitive deficit in Amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 54(4):782-787.
32. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, et al. (2012) Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatrics & gerontology international 12(2):207-214.
33. Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPARγ agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5(3):481-489.
34. Kummer MP, Heneka MT (2008) PPARs in Alzheimer's disease. PPAR research 2008:8.
35. Wang J, Ho L, Chen L, Zhao Z, Zhao W, et al. (2007) Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. Journal of Clinical Investigation 117(11):3393-3402.
36. Hajjar I, Brown L, Mack WJ, Chui H (2012) Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Archives of neurology 69(12):1632-1638.
37. Plum L, Schubert M, Brüning JC (2005) The role of insulin receptor signaling in the brain. Trends in Endocrinology & Metabolism 16(2):59-65.
38. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, et al. (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28(6):809-822.
39. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, et al. (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. The Journal of clinical investigation 122(4):1316.
40. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, et al. (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. The Journal of clinical investigation 122(4):1339.
41. Saura CA, Valero J (2011) The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Reviews in the neurosciences 22(2):153-169.
42. Parkinson H, Kapushesky M, Kolesnikov N, Rustici G, Shojatalab M, et al. (2009) ArrayExpress update-from an archive of functional genomics experiments to the atlas of gene expression. Nucleic acids research (suppl 1): D868-D872.
43. Shindo T, Takasaki K, Uchida K, Onimura R, Kubota K, et al. (2011) Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. Biological & pharmaceutical bulletin 35(12):2141-2147.
44. Ahn J, Yoon Y, Park C, Shin E, Park S (2011) Integrative gene network construction for predicting a set of complementary prostate cancer genes. Bioinformatics 27(13):1846-1853.